Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30,038Revenue $M580Net Margin (%)-117.4Altman Z-Score12.1
Enterprise Value $M29,692EPS $-3.1Operating Margin %-108.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-117.0Higher ROA y-yN
Price/Book30.610-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales48.55-y EBITDA Growth Rate %--Current Ratio4.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-62.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M244ROIC % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXKen Fisher 2015-06-30 Reduce$116.43 - $135.82
($125.88)
$ 123.23-2%Reduce 0.18%4,378
VRTXVanguard Health Care Fund 2015-03-31 Reduce-0.08%$107.88 - $134.25
($119.81)
$ 123.233%Reduce 2.80%9,533,911
VRTXGeorge Soros 2015-03-31 Buy 0.07%$107.88 - $134.25
($119.81)
$ 123.233%New holding56,912
VRTXKen Fisher 2015-03-31 Add$107.88 - $134.25
($119.81)
$ 123.233%Add 0.18%4,386
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 123.239%Reduce 16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 123.2330%Reduce 31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 123.2376%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 123.2377%Sold Out0
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 123.2377%New holding6,753
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 123.2356%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 123.2356%New holding10,000
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 123.2377%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 123.2355%Add 19.00%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 123.2367%Add 140.58%5,990,000
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 123.2367%Sold Out0
VRTXVanguard Health Care Fund 2013-03-31 Add0.05%$43.65 - $54.97
($48.01)
$ 123.23157%Add 10.97%2,489,800
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 123.23157%Reduce 23.44%191,032
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 123.23130%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 123.23130%Sold Out0
VRTXNWQ Managers 2012-06-30 Reduce-0.27%$35.75 - $65.62
($50.92)
$ 123.23142%Reduce 83.86%188,842
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2015-07-22Sell10,400$130.92-4.14view
BOGER JOSHUA SDirector 2015-07-15Sell12,200$133.98-6.33view
Silva Paul MSVP & Corp Controller 2015-07-13Sell1,125$123.791.38view
BOGER JOSHUA SDirector 2015-07-08Sell11,700$122.742.25view
Chodakewitz JeffreyEVP GMDA, CMO 2015-07-02Sell2,291$129.36-2.98view
BOGER JOSHUA SDirector 2015-07-01Sell11,700$125.6-0.08view
BOGER JOSHUA SDirector 2015-06-24Sell11,700$130.41-3.77view
BOGER JOSHUA SDirector 2015-06-17Sell11,700$123.91.29view
BOGER JOSHUA SDirector 2015-06-10Sell11,700$125.020.38view
BOGER JOSHUA SDirector 2015-06-03Sell11,700$125.81-0.25view

Quarterly/Annual Reports about VRTX:

News about VRTX:

Articles On GuruFocus.com
Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
Business Highlights Jul 24 2015
What to Watch in the Week Ahead and on Monday, July 27 Jul 24 2015
Will The High Cost Of Vertex's New Cystic Fibrosis Drug Push The U.S. To European Style Pricing? Jul 22 2015
How High? The Backlash Over Rising Prescription Drug Prices Gains Steam Jul 21 2015
Sector names that show potential Jul 20 2015
Biotech Stocks: Safe vs Sexy Jul 17 2015
UAW Trust Sought Drug-Price Risk Disclosures Jul 16 2015
What Will Gilead Buy Next? 4 Possible Targets Jul 15 2015
What's Wrong With Vertex? Jul 14 2015
Vertex to Announce Second Quarter 2015 Financial Results on July 29 Jul 14 2015
Vertex to Announce Second Quarter 2015 Financial Results on July 29 Jul 14 2015
Gilead's next target? Jul 09 2015
What to Buy in Biotech Jul 09 2015
Regeneron, Amgen Downgraded As Biotech Seen Slowing Jul 09 2015
The Zacks Analyst Blog Highlights: Vertex, Biogen, Applied Genetic, Gilead and Alexion - Press... Jul 09 2015
Biotech Stock Roundup: Vertex CF Drug Approved, Biogen Strikes Deal for Gene Therapy - Analyst Blog Jul 08 2015
Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside Jul 06 2015
Evercore ISI Analyst Gives Highlights From Vertex's Orkambi Call Jul 05 2015
What You May Have Missed In Biotech: Celgene's $1B Bet On Cancer Immunotherapy, And A New CF Drug Jul 03 2015
Vertex’s $259,000 Cystic Fibrosis Drug Gets FDA Approval Jul 02 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK